AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Kiniksa Pharmaceuticals CFO Mark Buys Shares, Sells Shares on December 8, 2025.
ByAinvest
Wednesday, Dec 10, 2025 5:25 pm ET1min read
Kiniksa Pharmaceuticals International, plc [KNSA] has recently disclosed that Ragosa Mark, the company's Chief Financial Officer, has made several transactions involving the purchase and sale of shares. On December 8, 2025, Mr. Mark acquired a total of 42,941 shares at an average price of $11.97 per share. Specifically, he purchased 16,164 shares at $11.1 per share, 16,165 shares at $11.97 per share, and 10,512 shares at $10.76 per share. Additionally, on the same day, he sold 42,841 shares at $41.49 per share. These transactions were reported in accordance with regulatory requirements.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet